Nivolumab

Generic Name
Nivolumab
Brand Names
Opdivo, Opdualag
Drug Type
Biotech
Chemical Formula
-
CAS Number
946414-94-4
Unique Ingredient Identifier
31YO63LBSN
Background

Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...

Indication

Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...

Associated Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
Associated Therapies
Complete Surgical Resection, Neoadjuvant Therapies
Clinical Trials
Related News

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

First Posted Date
2023-01-09
Last Posted Date
2024-12-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
1875
Registration Number
NCT05675410
Locations
🇺🇸

Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

🇺🇸

Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 307 locations

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

First Posted Date
2022-12-23
Last Posted Date
2024-02-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
100
Registration Number
NCT05663710
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 2
Recruiting
Conditions
Hodgkin Lymphoma
Interventions
Drug: Nivolumab
First Posted Date
2022-12-21
Last Posted Date
2022-12-21
Lead Sponsor
National Research Center for Hematology, Russia
Target Recruit Count
50
Registration Number
NCT05660993
Locations
🇷🇺

National Research Center for Hematology, Moscow, Russian Federation

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

First Posted Date
2022-12-19
Last Posted Date
2024-11-01
Lead Sponsor
Perspective Therapeutics
Target Recruit Count
52
Registration Number
NCT05655312
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Saint Louis University Hospital, Saint Louis, Missouri, United States

🇺🇸

Mayo Clinic Rochester, Rochester, Minnesota, United States

and more 6 locations

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

First Posted Date
2022-12-15
Last Posted Date
2023-09-08
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
80
Registration Number
NCT05652673
Locations
🇳🇱

Erasmus MC, Rotterdam, Netherlands

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

First Posted Date
2022-12-12
Last Posted Date
2024-10-26
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
26
Registration Number
NCT05647265
Locations
🇺🇸

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

🇺🇸

Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States

🇺🇸

Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 120 locations

Study of Novel Treatment Combinations in Patients With Lung Cancer

First Posted Date
2022-12-01
Last Posted Date
2024-11-14
Lead Sponsor
Gilead Sciences
Target Recruit Count
593
Registration Number
NCT05633667
Locations
🇧🇷

Hospital Mae de Deus, Porto Alegre, Brazil

🇧🇷

Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil

🇬🇧

Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom

and more 80 locations

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

First Posted Date
2022-11-29
Last Posted Date
2024-11-08
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
33
Registration Number
NCT05629546
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

First Posted Date
2022-11-22
Last Posted Date
2024-08-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
220
Registration Number
NCT05625412
Locations
🇺🇸

The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles, California, United States

🇺🇸

Local Institution - 0019, Los Angeles, California, United States

🇦🇷

Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina

and more 35 locations

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

First Posted Date
2022-11-09
Last Posted Date
2023-04-06
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1975
Registration Number
NCT05611229
Locations
🇺🇸

Novartis Investigative Site, East Hanover, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy